Watch Prof. Andrea Maier explain the critical role of muscle in overall health, and describe the significance of World Sarcopenia Day 2022.
World Sarcopenia Day July 4th 2022
World Sarcopenia Day (July 4th 2022) serves as an opportunity to raise awareness and knowledge for the prevalent disease, sarcopenia. Sarcopenia is a muscle disease that can drastically impede upon individuals physical function, independence, and overall quality of life. It is therefore vital that attention is given to appropriately diagnosing and managing this disease in order to maintain and promote overall well-being. Join us in celebration of this important day! On this page you will find materials that describe the disease in more detail, the appropriate management and treatment approaches, as well as the evidence to date on the muscle-targeted oral nutritional supplement containing ActiSyn™ (100% whey protein, leucine and vitamin D) and its key role in sarcopenia management.
Importance of World Sarcopenia Day 2022
Sarcopenia: How to recognize, diagnose and manage in clinical practice
Use this pocket card developed by Prof. Andrea Maier to understand the critical, yet simple steps to recognize and diagnose sarcopenia in clinical practice, as well as the role of protein supplementation and resistance exercise in management of the disease.
Sarcopenia: What, Who, Why, Impact and Treatment
Infographic outlining the established definition of sarcopenia, its prevalence along the patient journey, its underling lying cause and driving factors as well as the appropriate treatment methods for sarcopenia.
The role of muscle-targeted ONS in rehabilitation in sarcopenic patients
The IRIS (Improving Rehabilitation in Sarcopenia) study highlights the importance of intervention with muscle-targeted ONS containing ActiSyn (100% whey protein, leucine and vitamin D) combined with exercise in sarcopenic patients in improving functional outcomes, increasing independence and reducing rehabilitation stay.
Clinical Value of Muscle-Targeted ONS with ActiSyn
The muscle-targeted oral nutritional supplement containing ActiSyn™ (100% whey protein, leucine and vitamin D) has 10 years of evidence behind it, demonstrating its efficacy across key clinical outcomes across varying patient populations and settings. View the complete evidence booklet to learn about the robust evidence to date.
Latest evidence
Click here to read the latest narrative review by Dr. Emanuele Cereda wherein he describes the latest evidence to date describing why muscle-targeted ONS with ActiSyn should be considered as first-line nutritional support for sarcopenia.
- NHS, UK, Comprehensive model of personalised care. July 11, 2020.
- Cookie Statement
- Privacy Statement
- Terms of Use
- Danone Ethics Line
- Site Map
Are you a healthcare professional or (carer of) a diagnosed patient?
The product information for this area of specialization is intended for healthcare professionals or (carers of) diagnosed patients only, as these products are for use under healthcare professional supervision.
Please click ‘Yes’ if you are a healthcare professional or (carer of) a diagnosed patient, or ‘No’ to be taken to a full list of our products.
The information on this page is intended for healthcare professionals only.
If you aren't a healthcare professional, you can visit the page with general information, by clicking 'I'm not a healthcare professional' below.